Cipher Pharmaceuticals Inc. (CPH.TO)
| Previous Close | 2.2500 |
| Open | 2.2600 |
| Bid | 2.2100 x 0 |
| Ask | 2.3000 x 0 |
| Day's Range | 2.2300 - 2.3100 |
| 52 Week Range | 1.5400 - 2.8000 |
| Volume | |
| Avg. Volume | 40,466 |
| Market Cap | 59.071M |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | 9.78 |
| EPS (TTM) | 0.2290 |
| Earnings Date | Mar 16, 2022 - Mar 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.14 |
- CNW Group
Cipher Pharmaceuticals Schedules Q2 2022 Earnings Release and Conference Call
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q2 2022 financial results on Thursday, August 11, 2022 after market close. The Company will also host a conference call on Friday, August 12, 2022 at 8:30am ET to discuss the results and corporate developments.
- Simply Wall St.
Should Weakness in Cipher Pharmaceuticals Inc.'s (TSE:CPH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
With its stock down 3.8% over the past three months, it is easy to disregard Cipher Pharmaceuticals (TSE:CPH). But if...
- CNW Group
Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders and Thanks Director Dr. John Mull
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company's management information circular dated May 13, 2022 were approved by the requisite majority of votes cast at the meeting. In particular, shareholders approved the election of all director nominees, the re-approval of Ernst & Young L
